857970-06-0

Basic information

• Product Name: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-
• Synonyms: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-;6-Bromothiazolo[4,5-b]pyridin-2-amine
• CAS NO: 857970-06-0
• Molecular Formula: C6H4BrN3S
• Molecular Weight: 230.08506
• Mol File: 857970-06-0.mol

Chemical Properties

• Boiling Point: 362.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.950±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: -0.33±0.50(Predicted)
• CAS DataBase Reference: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(857970-06-0)
• EPA Substance Registry System: Thiazolo[4,5-b]pyridin-2-aMine, 6-broMo-(857970-06-0)

Safety Data

• Hazardous Substances Data: 857970-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Thiazolo[4,5-b]pyridin-2-amine, 6-bromois used as a building block for the synthesis of various organic compounds in pharmaceutical research. Its unique structure and reactivity contribute to the development of novel drug candidates with potential therapeutic applications.
Used in Drug Synthesis:
In the pharmaceutical industry, Thiazolo[4,5-b]pyridin-2-amine, 6-bromois employed as a key intermediate in the synthesis of new drugs. Its presence in the molecular structure can impart specific properties and functionalities, enhancing the drug's efficacy and selectivity.
Used in Material Science:
Thiazolo[4,5-b]pyridin-2-amine, 6-bromocan also be utilized in material science for the development of specialized materials with unique properties. The presence of the bromine atom and the heterocyclic structure may contribute to the creation of materials with tailored characteristics for specific applications.

InChI:InChI=1S/C6H4BrN3S/c7-3-1-4-5(9-2-3)10-6(8)11-4/h1-2H,(H2,8,9,10)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 15192-76-4 copper(II) thiocyanate 
• 35486-42-1 2-amino-3,5-dibromopyridine 
• 31545-35-4 1-(3,5-dibromopyridin-2-yl)thiourea 
• 31430-58-7 N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide 
• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 588729-97-9 N-(6-bromo[1,3]thiazolo[4,5-b]pyridin-2-yl)benzamide 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 960535-44-8 6-bromo-2-chlorothiazolo[4,5-b]pyridine 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Chemical synthesis method of thiazolo[4,5-b]pyridyl-6-carboxylic acid

The invention relates to a chemical synthesis method of thiazolo[4,5-b]pyridyl-6-carboxylic acid. According to the method, starting from 3,5-dibromo-2-aminopyridine as a raw material, five steps of reactions comprising an acylation reaction, a cyclization reaction, a diazotization reaction, a carbonyl insertion reaction and a hydrolysis reaction are carried out to synthesize the thiazolo[4,5-b]pyridyl-6-carboxylic acid. An efficient synthesis method is provided for synthesis of the compound.

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY

The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R1R2)-C(=O)-NR3R4 and a group represented by the formula: -R5, a broken line represents the presence or the absence of a bond, Z is -NR6-, =N-, -O-, or -S-, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.